Vivesto Investor Relations Material
Latest events
R&D Update
Vivesto
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Vivesto
Access all reports
Segment Data
Access more data
Net sales by
Source
Sales of goods
Expenses by
Financials
Vivesto AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The company offers XRP988/Apealea/Doxophos that is a drug consisting of doxorubicin encapsulated in an oil-based carrier system for injection; and Paclical/Apalutamide that is an oral formulation of a pure antiandrogen. It serves various markets through third party distributors. The company was formerly known as Oasmia Pharmaceutical AB and changed its name to Vivesto AB in March 2022. The company was founded in 1988 and is headquartered in Solna, Sweden.
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇸🇪 Sweden